Pericarbon Freedom HAEMODYNAMIC AND CLINICAL RESULTS
AORTIC VALVE REPLACEMENT WITH THE SORIN PERICARBON FREEDOM STENTLESS PROSTHESIS: 7 YEARS OF CLINICAL EXPERIENCE IN 130 PATIENTS
A. D’Onofrio, S. Auriemma, P. Magagna, A. Favaro, A. Cannarella, C. Piccin, M. Bilotta, N. Abbiate, N. Lamascese, A. Fabbri
Division of Cardiac Surgery, San Bortolo Hospital, Vicenza, Italy
The Journal of Thoracic and Cardiovascular Surgery 2007;134:491-5
|
Number of patients |
130 consecutive |
|
Implant time frame |
Jul 1999 - Nov 2005 |
|
Mean age |
76 ± 5 |
|
Distribution |
56.1 males |
|
Concomitant procedure |
38.4% |
|
Average follow up |
2.5 ± 1.8 yrs |
|
Total cumulative follow up |
324 pts/yrs |
OBJECTIVES
The aim of this study was to assess midterm clinical and haemodynamic results of aortic valve replacement with Sorin Pericarbon Freedom (SPF) stentless bioprosthesis.
RESULTS
Haemodynamic Results
“The haemodynamics of the SPF bioprosthesis, in terms of transvalvular gradients and effective orifice areas, have been shown to be similar to those of other routinely used stentless valves.”
“Although this might appear to be rather low, one must take into consideration that 4 of 6 late deaths were sudden/ unexpected/ unexplained, and 1 was due to a massive hemorrhage during reoperation. Furthermore, there are only a few patients at risk after 5 years, and this fact inevitably causes a quick decrease of the Kaplan-Meier curve”.
“In our experience we did not find any structural valve deterioration, and in the 3 explanted valves, the leaflets were undamaged and without any sign of calcification.”
|
|
LIN. RATES (%/pt-yr) |
|
Prosthetic valve endocarditis |
0.6 |
|
Thromboembolism |
0.3 |
|
Hemorrhage |
0.3 |
|
Reoperation |
0.9 |
CONCLUSIONS
“The SPF stentless bioprosthesis appears to be a good option for aortic valve replacement in elderly patients and in those with contraindications to oral anticoagulant drugs. It provided good results in terms of valve durability and freedom form valve-related complications. Echocardiographic data showed that the haemodynamic performance of the SPF bioprosthesis is excellent and overlaps that of other commercially available stentless bioprostheses.”
.pdf